TPCW
DNLI icon

TD Private Client Wealth’s Denali Therapeutics DNLI Stock Holding History

TD Private Client Wealth’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.36K Hold
71
– – ﹤0.01% 1341
2025
Q4 		$1.17K Hold
71
– – ﹤0.01% 1347
2025
Q3 		$1.03K Buy
+71
New +$1.02K ﹤0.01% 1334

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TD Private Client Wealth's DNLI Position: Q1 2026 in Review

TD Private Client Wealth held its Denali Therapeutics (DNLI) position steady in Q1 2026 at 71 shares worth $1.36K. The position accounts for ﹤0.01% of the portfolio, ranked #1341.

TD Private Client Wealth first reported a position in DNLI in Q3 2025 and has held it in 3 quarters since. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • TD Private Client Wealth held 71 shares of Denali Therapeutics worth $1.36K as of Q1 2026.
  • TD Private Client Wealth left its Denali Therapeutics share count unchanged in Q1 2026.
  • Denali Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q1 2026, its #1341 holding.
  • TD Private Client Wealth first reported a position in Denali Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.